CTLA-4 Antigen

• 

  Subject Areas on Research

  • A genome-wide association study of myasthenia gravis. 
  • Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients. 
  • Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. 
  • Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. 
  • CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States. 
  • CTLA-4-Mediated inhibition of early events of T cell proliferation. 
  • CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. 
  • Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. 
  • Checkpoint blockade in combination with cancer vaccines. 
  • Checkpoint inhibitors in hematological malignancies. 
  • Costimulator dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice. 
  • Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. 
  • Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. 
  • Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. 
  • Cytotoxic T-lymphocyte-associated antigen-4. 
  • Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. 
  • Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. 
  • Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. 
  • High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. 
  • Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. 
  • Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. 
  • Immune checkpoint blockade: Releasing the brake towards hematological malignancies. 
  • Immune checkpoint modulation enhances HIV-1 antibody induction. 
  • Immunomodulation of human CD8⁺ T cells by thymoglobulin in vitro. 
  • Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. 
  • Immunotherapy for osteosarcoma: Where do we go from here? 
  • Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. 
  • Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. 
  • Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression. 
  • Irradiation and immunotherapy: From concept to the clinic. 
  • K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation. 
  • Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. 
  • Molecular basis of T cell inactivation by CTLA-4. 
  • Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. 
  • Natural genetic variants influencing type 1 diabetes in humans and in the NOD mouse. 
  • Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. 
  • Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model. 
  • Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. 
  • Role of interleukin 12 and costimulators in T cell anergy in vivo. 
  • Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. 
  • Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. 
  • Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. 
  • T cells specific for α-myosin drive immunotherapy-related myocarditis. 
  • Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. 
  • The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. 
  • Update on anti-CTLA-4 antibodies in clinical trials. 
  • Upregulation of molecules associated with T-regulatory function by thymoglobulin pretreatment of human CD4+ cells.